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Background: Accumulating evidence suggests that breast cancer involves tumour-initiating cells (TICs), which play
a role in initiation, metastasis, therapeutic resistance and relapse of the disease. Emerging drugs that target TICs
are becoming a focus of contemporary research. Mitocans, a group of compounds that induce apoptosis of cancer
cells by destabilising their mitochondria, are showing their potential in killing TICs. In this project, we investigated
mitochondrially targeted vitamin E succinate (MitoVES), a recently developed mitocan, for its in vitro and in vivo
efficacy against TICs.
Methods: The mammosphere model of breast TICs was established by culturing murine NeuTL and human
MCF7 cells as spheres. This model was verified by stem cell marker expression, tumour initiation capacity and
chemotherapeutic resistance. Cell susceptibility to MitoVES was assessed and the cell death pathway investigated.
In vivo efficacy was studied by grafting NeuTL TICs to form syngeneic tumours.
Results: Mammospheres derived from NeuTL and MCF7 breast cancer cells were enriched in the level of stemness,
and the sphere cells featured altered mitochondrial function. Sphere cultures were resistant to several established
anti-cancer agents while they were susceptible to MitoVES. Killing of mammospheres was suppressed when the
mitochondrial complex II, the molecular target of MitoVES, was knocked down. Importantly, MitoVES inhibited
progression of syngeneic HER2high tumours derived from breast TICs by inducing apoptosis in tumour cells.
Conclusions: These results demonstrate that using mammospheres, a plausible model for studying TICs, drugs that
target mitochondria efficiently kill breast tumour-initiating cells.
Keywords: Tumour-initiating cells, Mitochondrially targeted vitamin E succinate, Complex II, Mitochondrial potential,
Mitochondria, Breast cancerBackground
Breast cancer, a neoplastic disease with high level of in-
cidence and mortality, is the prevalent cancer in females
[1, 2]. One reason for high rate of breast cancer, its meta-
static potential and, in many cases, resistance to therapy,
is the presence of tumour-initiating cells (TICs) [3, 4] that
represent a small tumour subpopulation with the ability to
self-renew and drive tumour growth [5, 6]. Recent re-
search provides strong evidence for the contribution of
TICs to tumour (re-) initiation and progression [7-12].* Correspondence: l.dong@griffith.edu.au; j.neuzil@griffith.edu.au
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unless otherwise stated.Therefore, specific therapies targeted at TICs may sup-
press tumour (re-) growth, perhaps even eliminating the
pathology [13, 14]. Development of anti-TIC approaches
is an emerging focus of research, and a group of com-
pounds with anti-cancer properties acting by destabilising
mitochondria, ‘mitocans’, appear to be efficient against
TICs [15].
Mitocans define small compounds that induce apop-
tosis of malignant cells via targeting mitochondria. They
are classified into several categories according to their
molecular target [16]. Mitocans from the vitamin E (VE)
group, epitomised by α-tocopheryl succinate (α-TOS),
affect the mitochondrial complex II (CII) by interferingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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age of electrons and generation of reactive oxygen species
(ROS), which trigger selective apoptosis in cancer cells
[17, 18]. To promote its selective mitochondrial uptake
driven by mitochondrial potential (ΔΨm,i), we tagged α-
TOS with the delocalised cation triphenylphosphonium
(TPP+) to prepare mitochondrially targeted vitamin E suc-
cinate (MitoVES). This agent preferentially associates with
mitochondria of cancer cells and kills malignant cells
more efficiently than the parental compound [19, 20].
Selectivity of agents like MitoVES for malignant cells
is based on the relatively high ΔΨm,i of cancer cells [21].
Recent reports document that TICs have higher ΔΨm,i
than differentiated cancer cells [22]. Therefore we de-
cided to establish a model of breast cancer TICs and test
the anti-cancer efficacy of MitoVES.
Methods
Cell culture and sphere preparation
Breast cancer NeuTL cells derived from tumours of
transgenic FVB/N c-neu mice [23] and human MCF7
cells obtained from the ATCC were cultured in DMEM
with 10 % FBS and antibiotics. Spheres were prepared by
seeding cells at the density of 105/ml of ‘sphere medium’
composed of DMEM-F12 plus cell proliferation supple-
ment (Neurocult), 10 ng/ml mouse or human recombin-
ant EGF, 5 ng/ml recombinant FGF (R&D Systems), and
2 mM L-glutamine.
Quantitative RT-PCR (qPCR)
Total RNA from cells or tissues was extracted using the
RNeasy kit (Qiagen). The Revertaid First-Strand Synthe-
sis System plus random hexamer primers (Thermo Fi-
scher Scientific) were used to transcribe total RNA into
cDNA. Using specific primers, genes of interest were
evaluated with 2xSYBR Green (Qiagen) by means of the
Eco qPCR System (Illumina). Target genes were normal-
ised to GAPDH, and change in gene expression deter-
mined using the ΔΔCt method (see Additional file 1 for
primer sequences).
Cell cycle analysis
Adherent or sphere cells were fixed in 70 % ethanol
overnight at -20 °C, pelleted and re-suspended in the
staining solution (50 μg/ml propidium iodide, 100 μg/ml
RNase A, 0.1 % Triton X-100). After 40 min incubation
at 37 °C, samples were accessed with the Fortessa flow
cytometer (BectonDickonson) and data analysed using
the FlowJo software (TreeStar).
Evaluation of mitochondrial membrane potential (ΔΨm,i),
reactive oxygen species (ROS), cell death and viability
Standard flow cytometric methods were applied utilising
the following fluorescent probes. ΔΨm,i was estimatedwith tetramethylrhodamine methyl ester (TMRM), and
ROS were evaluated using dichlorofluorescein diacetate
(DCF) or MitoSOX. Apoptosis was evaluated using annexin
V-FITC/propidium iodide. Viability was assessed using the
MTTassay.
Succinate dehydrogenase (SDH) and succinate quinone
reductase (SQR) activity assays
For SDH activity, cells were seeded in 96 well plates at
10,000 cells per well and allowed to recuperate over-
night. They were then incubated with 20 mM succinate
for 1 h before 10 μl MTT reagent (5 mg/ml) was added
to each well, followed by 4-h incubation at 37 °C and 5 %
CO2. Media was then removed and formazan dissolved in
DMSO, and absorbance was measured at 570 nm [19, 20].
For SQR activity, 40 μg of protein lysate extracted before
the assay (Cell Lysis Buffer, Cell Signaling) were added to
1 ml of the SQR assay buffer (10 mM KH2PO4, pH 7.8,
2 mM EDTA, 1 mg/ml BSA, 80 μM DCPIP, 4 μM rote-
none, 0.2 mM ATP and 10 mM succinate) and incubated
at 30 °C for 10 min. Decylubiquinone was added to a final
concentration of 80 μM, and absorbance assessed each
minute for 30 min at 600 nm [19, 20].
High-resolution respirometry
Oxygen consumption was assessed using the Oxygraph-
2 k high-resolution respirometer (Oroboros). Intact cell
respiration was evaluated with cells suspended in the
RPMI medium without serum. Oxygen consumption
was evaluated for cellular routine respiration, oligomycin-
inhibited leak respiration, FCCP-stimulated uncoupled
respiration (ETS) and rotenone/antimycin-inhibited re-
sidual respiration (ROX). Respiration via mitochondrial
complexes was evaluated using saponin-permeabilised
cells or shredded tumour tissue, suspended in the mitochon-
drial respiration medium MiR06. Oxygen consumption was
evaluated for routine respiration, CI-linked respiration, (CI +
CII)-linked respiration, maximum uncoupled respiration,
CII-linked uncoupled respiration as well as residual oxy-
gen consumption [24].
Western blotting (WB)
Cells and homogenised tumour tissue were lysed, and
total protein (30 μg) resolved by SDS-PAGE and trans-
ferred to PVDF membranes, which were probed with
following antibodies: EpCAM, erbB2 (both from Sigma-
Aldrich), caspase-9, caspase-8, cleaved caspase-3, VDAC,
COX IV, SDHA (all from Cell Signaling), CD44, HSP60,
actin (all from Abcam), CD133, PARP-1/2 (both from
Santa Cruz), and SDHC (Novus Biologicals). ECL western
blotting substrate (Thermo Scientific) and ChemiDoc™
XRS+ System (BioRad) were used to visualise and evaluate
the blots.
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Mitochondria were isolated following a standard proto-
col, and protein concentration assessed using the BCA
assay. NativePAGE Novex Bis-Tris (4-16 % gradient)
gels (Life Technologies) were used for electrophoresis of
digitonin-solublised mitochondria. After electrophor-
esis, gels were incubated in the SDS-PAGE 1 × running
buffer for 5 min, and the protein transferred to a PVDF
membrane probed with specific antibodies against mito-
chondrial complex I (CI) (NUDFA9), CII (SDHA and
SDHB), complex III (Core1), complex IV (COX Va) and
complex V (ATPaseβ) (all antibodies from Cell Signal-
ing). HSP60 was used as loading control.Preparation of SDHC knock-down cells
MCF7 cells were transfected with non-silencing (N.S.) or
SDHC shRNA (both SABiosciences) using the FuGENE
HD reagent as per standard protocol. Selected clones were
tested for SDHC mRNA and protein, and the clone with
lowest level of SDHC used in experiments.Tumour formation and MitoVES treatment
Tumours were established in female FVB/N c-neu mice
(~2 months old) by subcutaneous grafting of NeuTL ad-
herent or sphere cells at 3x106 per animal. Mice were regu-
larly checked by the Vevo770 ultrasound imaging (USI)
apparatus equipped with a 30-μm resolution scan-head
(VisualSonics). As soon as tumours reached ~50 mm3, ani-
mals were treated by intraperitoneal (i.p.) injection of
MitoVES (25 nmol per gram of body weight) in corn oil
containing 4 % ethanol every 3-4 d. Control mice were
injected with the same volume (100 μl) of the excipient.
Tumour progression was assessed by USI, which enables
3D reconstruction of tumours and precise quantifica-
tion of their volume. Tumours were harvested, fixed in
and paraffin-embedded. The blocks were cut into 1 μm
sections stained with H&E or incubated with primary
antibody and biotinylated secondary antibody. The ABC
kit (Vector Laboratories) was used to amplify the signal.
Mayer’s haematoxylin was used for counterstaining the
nuclei. All animal experiments were performed accord-
ing to the guidelines of the Australian and New Zealand
Council for the Care and Use of Animals in Research and
Teaching and were approved by the Griffith University
Animal Ethics Committee.Statistical analysis
All data are mean values of at least three independent ex-
periments ± S.D. The unpaired Student’s t test or one-way
ANOVA were used to assess statistical significance. Differ-
ences with p < 0.05 were regarded as significant. Images
are representative of three independent experiments.Results
NeuTL and MCF7 spheres are enriched in TICs
To establish an in vitro model to study breast TICs, we
grew NeuTL and MCF7 cells under condition that pro-
motes sphere generation (Fig. 1 A, B). Both cell lines
formed mammospheres within 3-5 days, reaching ~50 μm
in diameter. To verify spheres as a model of breast
TICs, mRNA level of a series of ‘stemness’ markers
was assessed. As can be seen in Fig. 1 C, NeuTL
spheres had higher expression of CD44, ALDH, EpCAM,
CD61, CD133, CD49 and CD29f, and lower expression of
CD24, compared to their adherent counterparts. MCF7
spheres featured higher level of CD44, CD133, OCT4,
ABCG2, ESA and c-Kit, and lower level of CD24
(Fig. 1 D).
To assess their tumour-propagating efficacy, sphere
and adherent cells were grafted into FVB/N c-neu mice.
As shown in Fig. 1 E, NeuTL spheres initiated USI-
detectable tumours within ~1 week, while there was a 2-
week delay for adherent cells. Adherent cell-derived tu-
mours progressed at about half the rate of the sphere-
derived ones, with an increase by 100 mm3 in 1.4 and
2.7 days, respectively. Morphologically, the two types of
tumours were similar, as documented by H&E staining
(Fig. 1 F). As assessed by WB and IHC (Fig. 1 G), the re-
ceptor tyrosine kinase erbB2 was highly and similarly
expressed in both tumour types.
Breast TICs are resistant to chemotherapeutic drugs but
sensitive to MitoVES
Figure 2 A documents that NeuTL spheres are more re-
sistant to doxorubicin and paclitaxel compared to their
adherent counterparts, consistent with their TIC nature.
α-TOS killed adherent and sphere NeuTL and MCF7
cells with similar efficacy, while MitoVES was more
efficient in killing sphere cells (Fig. 2 A, B). The IC50
values were higher for killing sphere cells by doxorubi-
cin and paclitaxel, while they were significantly lower
for MitoVES (Table 1). As the MTT assay used for cell
viability partially relies on the oxidative capacity of
mitochondria, the above results of α-TOS and MitoVES
may be affected to some extent. Therefore further cell
death assessment was carried on by flow cytometry
using PI and Annexin IV staining. We can see that
MitoVES also induced more cell death by apoptosis in
sphere vs. adherent cells, while α-TOS was inefficient
(Fig. 2 C-E). At 2 μM, MitoVES was more efficient in in-
ducing apoptosis in MCF7 sphere cells that 10 μM
parthenolide. While MitoVES at 2 μM was not very effi-
cient in causing apoptosis in adherent NeuTL cells, it
arrested their cell cycle (Fig. 2 F). The apoptotic nature
of cell death induced in sphere cells by MitoVES is doc-
umented in Fig. 2 G. Apart from apoptotic proteins acti-
vated by MitoVES treatment, there were also certain
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Fig. 1 NeuTL and MCF7 spheres are a plausible model of TICs. Neu TL cells were cultured in serum-containing and sphere medium (A) and
assessed for selected stemness genes by qPCR (C). MCF7 cells were cultured in adherent and ‘sphere’ medium (B) and assessed for selected
stemness genes by qPCR (D). (E) NeuTL adherent and sphere cells were grafted s.c. in FVB/N c-neu mice (106 cells per animal) and tumour
volume assessed using USI. The images on the right are representative USI scans of tumours taken on the given days (indicated by arrows in
the graph on the left). (F) Sections of tumours were stained by H&E for morphology, also showing regions of low and more differentiated
cancer cells. (G) Tumour sections were evaluated for the level of erbB2 using WB and IHC. In all cases, the level of stemness genes in sphere cells
was related to that in their adherent counterparts, set as 1. Data are mean values ± S.D. (n = 3). The symbol ‘*’ indicates statistically significant
differences in the level of mRNA in adherent and sphere cells with p < 0.05. Images in panels A, B, E, F and G are representative of three
independent experiments
Yan et al. BMC Cancer  (2015) 15:401 Page 4 of 12amounts of cleaved Caspase-8 and cleaved Caspase-9
documented in the control group, which may be due to
a small population of cells undergoing apoptosis among
the whole cell culture.Increased killing of breast TICs by MitoVES involves
mitochondria
MitoVES was more efficient in ROS generation in
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Fig. 2 (See legend on next page.)
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Fig. 2 Breast TICs are resistant to chemotherapeutic drugs but sensitive to MitoVES. Adherent and sphere NeuTL (A) and MCF7 cells (B) were
exposed to different concentrations of the agents for 24 h and viability assessed by the MTT assay. (C) NeuTL adherent and sphere cells were
exposed to 50 μM α-TOS or 2 μM MitoVES for 24 h and inspected by light microscopy. Adherent or sphere NeuTL (D) or MCF7 cells (E) were exposed
to α-TOS (50 μM), MitoVES (2 μM) or parthenolide (PTL; 10 μM) for 12 h and apoptosis evaluated using the annexin V/PI method. (F) Adherent NeuTL
cells were exposed to 2 μM MitoVES for 24 h and evaluated for cell cycle distribution. (G) NeuTL sphere and adherent cells were exposed to 5 μM
MitoVES for 12 h and full length and cleaved PARP, caspase-9 (C9), caspase-3 (C3) and caspase-8 assessed using WB with actin as loading
control. The level of full length and cleaved proteins was evaluated by densitometry and related to actin. Data are mean values ± S.D. (n = 3).
The symbol ‘*’ in panels A, B, D-F indicates statistically significant differences for adherent and sphere cells with p < 0.05. The symbol ‘*’ in
panel G indicates statistically significant differences in the expression of the full length and cleaved protein with p < 0.05. Images in panel C are
representative of three independent experiments
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suppressed respiration in sphere compared to adherent
cells (Fig. 3 C). That the two types of cells do not differ
in mitochondrial mass was confirmed by WB (Fig. 3 D).
Both NeuTL and MCF7 spheres showed considerably
higher ΔΨm,i potential than their adherent conterparts
(Fig. 3 E-G). Important role of ΔΨm,i in apoptosis induc-
tion by MitoVES follows from an experiment, in which
the mitochondrial uncoupler FCCP inhibited MitoVES-
induced killing in NeuTL and MCF7 spheres (Fig. 3 H, I).
The higher ΔΨm,i in sphere cells may enrich more
MitoVES into their mitochondrial, which contribute to
the high susceptibility of spheres upon MitoVES treat-
ment in comparison with their adherent counterparts.
Moreover, it is also found that NeuTL sphere cells have
higher expression of mitochondrial complexes (unpub-
lished data), some of which function as the molecular tar-
gets of MitoVES.
MitoVES affects mitochondrial complexes of breast TICs
We tested the contribution of CI and CII to respiration
of breast cancer cells and whether this is affected by
MitoVES. As shown in Fig. 4 A & B, oxygen consumption
was inhibited more at the level of CII, the target of the
agent. This was observed for both coupled and uncoupled
state of respiration. Native blue gel electrophoresis using a
mild detergent followed by WB was employed to assess
the change of mitochondrial respiratory complexes and
supercomplexes upon MitoVES treatment. Some de-
crease in the level of supercomplexes in cells treated
with MitoVES was observed after 2 and 4 h of exposure
to the drug (Fig. 4 C).Table 1 IC50 values (μM) for adherent and sphere cells exposed to v
Cell line Doxorubicin Paclitaxel
ADH SPH ADH
NeuTL 0.45 ± 0.07a 1.44 ± 0.17 0.26 ± 0.06
MCF7 n.d.b n.d. n.d.
MCF7 SDHClow n.d. n.d. n.d.
aIC50 values were calculated form the killing curves of the various adherent and sph
constructed using the MTT assay
bn.d.: not determinedMitoVES efficiently suppresses tumour growth
Adherent and sphere NeuTL cells were subcutaneously
injected in FVB/N c-neu mice to form syngeneic tu-
mours, after which MitoVES was administrated. As re-
vealed by USI, MitoVES efficiently suppressed growth of
tumours derived from both types of cells, such that after
7-8 injections, the tumour volume was lower by ~80 %
in the treated vs. control mice (Fig. 5 A, B). MitoVES sup-
pressed tumour growth by way of inducing apoptosis, as
documented by IHC using an antibody to cleaved caspase-
3 (Fig. 5 C, D). Assessment of respiration revealed that
MitoVES suppressed both CI- and CII-dependent respir-
ation of tumours (Fig. 5 E, F).
MitoVES kills breast TICs in a complex II-dependent
manner
Whether MitoVES induces apoptosis in breast TICs via
CII has not been tested. We therefore knocked down the
SDHC subunit of CII in MCF7 cells and found that
SDHClow MCF7 cells form spheres with low level of
SDHC, while SDHA is unaffected (Fig. 6 B). SDH activity
of CII, residing in SDHA, was only marginally affected,
while SQR activity of CII that requires intact SDHC was
suppressed (Fig. 6C). SDHClow MCF7 spheres feature high
level of stemness, as documented by several TIC markers
(Fig. 6D). Treatment of MCF7 sphere cells with MitoVES
homologues differing in the length of the aliphatic chain
linking the tocopheryl succinyl group TPP+ group re-
vealed that the short-chain homologues are inefficient in
ROS generation and apoptosis induction (Fig. 6 E, F),
pointing to CII as a target. SDHClow MCF7 spheres
showed higher viability in the presence of MitoVES thanarious anti-cancer agents
α-TOS MitoVES
SPH ADH SPH ADH SPH
>10 53 ± 4.5 58 ± 6.3 1.9 ± 0.31 1.1 ± 0.25
n.d. 24.8 ± 2.2 28.6 ± 1.9 4.52 ± 0.29 1.2 ± 0.25
n.d. n.d. n.d. n.d. 8.2 ± 1.3
ere cell cultures exposed to the agents for 24 h. The killing curves were














































































































































Fig. 3 Mitochondria play a role in high TIC killing activity of MitoVES. NeuTL adherent and sphere cells were exposed to 2 μM MitoVES for the
times shown and ROS evaluated by flow cytometry using DCF (A) or MitoSOX (B), and expressed as relative mean fluorescence intensity (MFI).
The histograms on the right are representative of individual readings. (C) Adherent and sphere NeuTL cells were assessed for routine respiration
in the absence or presence of MitoVES at the concentrations shown (μM). (D) Adherent and sphere NeuTL cells were probed by WB for the levels
of mitochondrial markers with actin as loading control. Adherent and sphere NeuTL (E) and MCF7 cells (F) were evaluated for ΔΨm,i using TMRM
and flow cytometry. The histogram in panel E on the right is an example of a reading for NeuTL cells. (G) Adherent and sphere NeuTL cells
were labelled with Hoechst to visualise nuclei and TMRM to document ΔΨm,i, and inspected by confocal microscopy. Sphere NeuTL (H) and
MCF7 (I) cells were exposed to 2 μM MitoVES for 24 h in the absence or presence of 10 μM FCCP and apoptosis evaluated. The histogram in
panel H on the right is an example of reading for NeuTL cells. Data are mean values ± S.D. (n = 3). The symbol ‘*’ in panels A-C, E and F indicates
statistically significant differences for adherent and sphere cells with p < 0.05. The symbol ‘*’ in panels H and I indicates statistically significant
differences in apoptosis induced in the presence and absence of FCCP with p < 0.05. Images in panels C and D are representative of three
independent experiments
Yan et al. BMC Cancer  (2015) 15:401 Page 7 of 12MCF7 spheres (Fig. 6G) with the IC50 value ~4-fold
higher (Table 1). SDHClow spheres were also more resistant
to MitoVES-induced apoptosis than their parental counter-
parts (Fig. 6H). Finally, thenoyltrifluoroacetate (TTFA), an
agent binding to CII’s UbQ site, prevented apoptosis in-
duced by MitoVES.Discussion
In this communication we describe a sphere model of
breast TICs that was adapted from research on neural
stem cells isolated from the CNS [25, 26] and that is
now accepted as a model for TIC studies in tissue cul-
ture [27-29]. The increased level of stemness in NeuTL
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Fig. 4 MitoVES affects mitochondrial complexes. (A) NeuTL spheres were treated with 2 μM MitoVE for and 4 h, before they were harvested,
permeablised with saponin and evaluated for respiration at the presence of substrates specific for CI and CII using the protocal indicated in more
detail in Materials and Methods. The abbreviations in the top left line graph are: L, leak; CI, complex I; CII, complex II; ETS, electron transfer system
(uncoupled resiraiton); CII’, uncoupled respiration via CII; ROX, residual respiration; PMG, pyruvate, malate and glutamate; cyt c, cytochrome c;
succ, succinate; F, FCCP; rot, rotenone; ama, antimycin A. (B) The respiration via CI and CII, and the uncoupled respiration via CI (CI’) and CII (CII’)
as derived from results shown in panel A is documented in control cells and cells exposed to 10 μM MitoVES for 2 and 4 h. (C) The mitochondrial
fraction, prepared from control NeuTL cells or cells exposed to 10 μM MitoVES for 2 and 4 h, was lysed in the presence of digitonin and subjected to
native blue gel electrophoresis as detailed in Materials and Methods. Specific subunits of individual complexes were detected using the antibodies as
shown. HSP60 was used as a loading control. The symbol ‘*’ in panels indicates statistically significant differences (p < 0.05) for the respiration after cells
were exposed to MitoVES
Yan et al. BMC Cancer  (2015) 15:401 Page 8 of 12and MCF7 spheres documented by expression of specific
markers [7, 30-34] is consistent with our recent results
using microarray chip approach [35]. Additional evidence
for the plausibility of spheres as a TIC model is docu-
mented by their higher tumour-initiating/propagating
efficacy [7]. Furthermore, the ‘sphere’ TICs were found re-
sistant to established, first line breast cancer therapeutics,
which more efficiently killed adherent breast cancer cells,
in line with the notion of general recalcitrant nature of
TICs [12, 36, 37].However, we found that breast TICs are killed more
efficiently by the mitocan MitoVES that by pathenolide,
an agent that was shown to cause death of TICs [38, 39].
MitoVES accumulates in mitochondria on the basis of
high ΔΨm,i due to the presence of the TPP
+ group [10,
11, 40], and this is consistent with the notion of higher
ΔΨm,i in stem cells [41]. MitoVES inhibits the respir-
ation of breast TICs via mitochondrial CI and, even
more, CII, causing the generation of ROS, which leads to

































































































































Fig. 5 MitoVES suppresses tumour progression. NeuTL adherent (A) and sphere cells (B) were grafted s.c. in FVB/N c-neu mice (106 cells per
animal) and tumour volume assessed in control and MitoVES-treated animals using USI. The images on the right are representative USI scans
of tumours taken on the given days (indicated by arrows in the graph on the left), the images on the right also show representative tumours
excised from mice at the end of the experiment. Tumours derived from adherent (C) and sphere NeuTL cells (D) were paraffin-embedded,
sectioned and probed by IHC for cleaved caspase-3. Tumour tissue was shredded and oxygen consumption evaluated using oxygraph. The respiration
via mitochondrial complexes was assessed and calculated (E, F). Data are mean values ± S.D. (n = 3). The symbol ‘*’ in panels A and B indicates
statistically significant differences in the volume of control and MitoVES-treated tumours with p < 0.05. Images in panels C and D are representative of
three independent experiments. The symbol ‘*’ in panel F and G indicates statistically significant differences in the respiration levels of control and
MitoVES-treated tumours with p < 0.05
Yan et al. BMC Cancer  (2015) 15:401 Page 9 of 12supercomplexes was inhibited, to some extent, as well.
MitoVES also suppressed progression of tumours derived
from both adherent and sphere cells, with similar efficacy.
The likely reason for this is that, when grafted, TICs dif-
ferentiate within the tumour microenvironment into
fast-proliferating tumour cells [28]. In tumour tissue, in-
hibition of cell respiration and induction of apoptosis
were also documented. Using the syngeneic FVB/N c-neu
mouse model, the drug effect against erbB2high breast
tumour was investigated under conditions of functional
immune system.
Of interest is the mechanism by which MitoVES kills
breast TICs. Our previous data document that themitochondrially targeted agent, similarly as the untar-
geted α-TOS, acts via interacting with the UbQ site of
CII [17-20]. That MitoVES acts also by targeting the
UbQ site in CII of breast TICs was first indicated by ex-
periments, in which shorter homologues of full length
MitoVES (11 carbons in the aliphatic chain linking the
tocopheryl succinyl and TPP+ groups) were correspond-
ingly less efficient in ROS generation and apoptosis
induction. Our recent molecular modelling indicates
that this linker has to be of certain length so that the
biologically active moiety of MitoVES can reach the
UbQ site of CII buried in the inner mitochondrial mem-
















































































































































































































































































Fig. 6 Apoptosis induced by MitoVES is dependent on complex II. (A) Adherent and sphere MCF7 cells were transfected with non-silencing (NS)
and SDHC shRNA and assessed for the level of SDHA and SDHC by qPCR and WB with actin as loading control. The graphs on the right show
the level of the SDHA and SDHC proteins in the sub-lines related to actin. (B) Parental and SDHClow MCF7 cells were grown in serum-containing
and ‘sphere’ medium and inspected by light microscopy. Parental and SDHClow MCF7 sphere cells were evaluated for SDH and SQR activities
(C) and for the level of stemness genes related to their level in MCF7 adherent cells set as 1 (D). MCF7 sphere cells were exposed to MitoVES
homologues at 5 μM for 1 h and assessed for ROS using MitoSOX (E) and for 12 h and assessed for apoptosis (F). Parental, NS and SDHClow MCF7
sphere cells, as shown, were exposed to MitoVES for 24 h (viability) or 12 h (apoptosis) and evaluated for viability using the MTT assay (G) and
apoptosis by the annexin V/PI method (H). (I) Adherent and sphere MCF7 cells were evaluated for apoptosis after 24 h exposure to 5 μM MitoVES
in the absence or presence of 10 μM TTFA. Data are mean values ± S.D. (n = 3). The symbol ‘*’ in panels A-C indicates statistically significant
differences for parental and SDHClow MCF7 cells, in panel D for adherent and sphere cells, in panels E and F for control and treated cells, in panels
G and H for parental and SDHClow MCF7 cells, and in panel I for cells treated in the absence and presence of TTFA, with p < 0.05. Images in panel
B are representative of three independent experiments
Yan et al. BMC Cancer  (2015) 15:401 Page 10 of 12positively charged end of the molecule at the matrix face
of the inner mitochondrial membrane [19, 20]. Import-
antly, spheres derived from MCF7 cells with knocked
down SDHC, lacking the UbQ site, were resistant toMitoVES treatment. Further, we show that the presence of
TTFA, a small molecule that is known to bind to CII’s
UbQ site [42], prevented the killing activity of MitoVES in
sphere cells. Collectively, our data convincingly document
Yan et al. BMC Cancer  (2015) 15:401 Page 11 of 12that MitoVES targets the UbQ site in CII to efficiently kill
breast TICs, and are consistent with the notion of CII as
an intriguing, novel target for anti-cancer agents [43]. Im-
portantly, subunits of CII only rarely mutate, such that
their mutational frequency is high in neoplasias like famil-
ial paraganglioma, but only one in one million breast can-
cer patients features a CII mutation [44].
Thus, we document a high killing activity of MitoVES
towards breast cancer TICs that are resistant to several
established anti-cancer agents. While our findings are of
translational significance, we also, for the first time, docu-
ment a link between mitochondrial complex II and killing
of tumour-initiating cells. The combination therapy of
MitoVES which effectively kills breast TICs and estab-
lished anti-cancer drugs targeting highly proliferating cells
may lead to a better tumour suppression results, which
will be further investigated in our future research.
Conclusions
In this project, mammosphere models for studying breast
TICs were established and verified. These cells featured al-
tered mitochondrial function. A mitochondrially targeted
anti-cancer compound, mitocan, epitomised by mitochond-
rially targeted vitamin E succinate (MitoVES), was found
very efficient in killing TICs, which has a potential transla-
tional relevance. Additional studies are needed to explore
the clinical value of our study for using MitoVES as an
agent that can potentially eradicate cancer stem-like cells
alone or in combination with other anti-cancer drugs.
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